Thursday, February 20, 2014

Avastin increases survival in women with advanced cervical cancer

MEDPAGE TODAY– Feb. 20, 2014 – In a trial of 452 patients with advanced cervical cancer that has recurred or did not respond to initial therapy, the women given Avastin in addition to combination chemotherapy survived an average of 17 months. That compared to 13.3 months for women treated with the combination chemotherapy alone. The study was published in the Feb. 20 New England Journal of Medicine.

No comments:

Post a Comment